查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
靜脈輸液市場規模、市場份額、應用分析、區域前景、增長趨勢、主要參與者、競爭戰略、預測，2023-2031
市場調查報告書
商品編碼
1283947

靜脈輸液市場規模、市場份額、應用分析、區域前景、增長趨勢、主要參與者、競爭戰略、預測，2023-2031

Intravenous Solutions Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 To 2031
出版日期: | 出版商: Acute Market Reports | 英文 115 Pages | 商品交期: 最快1-2個工作天內

價格

到 2031 年，IV 解決方案市場預計將增長 8.0%。 靜脈輸液提供多種營養素的組合，可幫助患者獲得所需的營養。 全球對 IV 解決方案的需求依然強勁，亞太地區增長迅猛。 靜脈注射產品受到嚴格監管，以確保質量和可用性。 儘管是一個成熟的市場，但它仍在不斷發展，從而實現穩定增長。

世界各地的靜脈輸液製造商和供應商都在不斷改進其產品的性質及其營銷和分銷方式。 一些大公司僱用直銷人員或獨立的分銷商、零售商和批發商。 它還採用替代供應方法讓製造商保持盈利。 在新興市場，代表製造商存儲和交付產品的第三方正在獲得很大的立足點。 這種供應商總是有足夠的庫存，因此他們可以提供響應迅速的客戶服務。 該市場中的其他銷售方法包括通過客戶或銷售服務代表進行的銷售、目錄的分發和推銷、電子採購功能和相關利益、電子郵件活動以及通過貿易出版物、交易會等進行的廣告宣傳。

市場進入者

Amanta Healthcare Ltd.、Axa Parenterals Ltd.、B. Braun Melsungen AG、Baxter International Inc.、Becton、Dickinson and Company、Eurolife Healthcare Pvt Ltd.、Fresenius Kabi AG、Grifols S.A、Henry Schein Inc.、ICU Medical , Inc., JW Life Science, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Salius Pharma Private Limited, Sichuan Kelun Pharmaceutical Co. Ltd., Soxa Formulations & Research (Pvt.) Ltd., Vifor Pharma Management Ltd.,等

內容

第一章前言

  • 報告內容
    • 報告的目的
    • 目標受眾
    • 主要產品
  • 市場細分
  • 調查方法
    • 第一階段 - 二次調查
    • 第二階段 - 初步調查
    • 第三階段 - 專家評審
    • 先決條件
    • 採用的方法

第 2 章執行摘要

第 3 章靜脈輸液市場：競爭分析

  • 主要供應商的市場定位
  • 供應商採用的策略
  • 主要產業戰略
  • 等級分析：2022 年與 2031 年

第 4 章靜脈輸液市場：宏觀分析和市場動態

  • 簡介
  • 2021-2031 年全球靜脈輸液市場價值
  • 市場動態
    • 市場驅動因素
    • 市場製約因素
    • 主要問題
    • 主要機會
  • 促進因素和抑制因素的影響分析
  • 蹺蹺板分析

第 5 章按類型劃分的靜脈輸液市場 2021-2031

  • 市場概覽
  • 增長和收益分析：2022 年與 2031 年
  • 市場細分
    • 部分腸外營養
      • 年齡段
    • 完全腸外營養
      • 年齡段

第 6 章按成分分類的靜脈輸液市場 2021-2031

  • 市場概覽
  • 增長和收益分析：2022 年與 2031 年
  • 市場細分
    • 碳水化合物
    • 維生素和礦物質
    • 單劑量氨基酸
    • 腸外脂肪乳劑
    • 其他

第 7 章最終用戶靜脈注射解決方案市場 2021-2031

  • 市場概覽
  • 增長和收益分析：2022 年與 2031 年
  • 市場細分
    • 醫院和診所
    • 門診手術中心
    • 家庭護理設置

第 8 章北美 IV 市場 2021-2031

  • 市場概覽
  • 2021-2031 年按類型分列的靜脈注射液市場
  • 2021-2031 年按成分分類的靜脈輸液市場
  • 2021-2031 年最終用戶的靜脈注射液市場
  • 2021-2031 年按地區劃分的靜脈輸液市場
    • 北美
      • 美國
      • 加拿大
      • 其他北美地區

第 9 章英國和歐盟靜脈注射解決方案市場 2021-2031

  • 市場概覽
  • 2021-2031 年按類型分列的靜脈注射液市場
  • 2021-2031 年按成分分類的靜脈輸液市場
  • 2021-2031 年最終用戶的靜脈注射液市場
  • 2021-2031 年按地區劃分的靜脈輸液市場
    • 英國和歐盟
      • 英國
      • 德國
      • 西班牙
      • 意大利
      • 法國
      • 其他歐洲地區

第 10 章亞太 IV 市場 2021-2031

  • 市場概覽
  • 2021-2031 年按類型分列的靜脈注射液市場
  • 2021-2031 年按成分分類的靜脈輸液市場
  • 2021-2031 年最終用戶的靜脈注射液市場
  • 2021-2031 年各地區靜脈輸液市場
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區

第 11 章拉丁美洲靜脈注射解決方案市場 2021-2031

  • 市場概覽
  • 2021-2031 年按類型分列的靜脈注射液市場
  • 2021-2031 年按成分分類的靜脈輸液市場
  • 2021-2031 年最終用戶的靜脈注射液市場
  • 2021-2031 年各地區靜脈輸液市場
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地區

第 12 章中東和非洲靜脈注射解決方案市場 2021-2031

  • 市場概覽
  • 2021-2031 年按類型分列的靜脈注射液市場
  • 2021-2031 年按成分分類的靜脈輸液市場
  • 2021-2031 年最終用戶的靜脈注射液市場
  • 2021-2031 年各地區靜脈輸液市場
    • 中東和非洲
      • 海灣合作委員會
      • 非洲
      • 其他中東和非洲地區

第13章公司簡介

  • Amanta Healthcare Ltd.
  • Axa Parenterals Ltd.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton Dickinson and Company
  • Eurolife Healthcare Pvt Ltd.
  • Fresenius Kabi AG
  • Grifols S.A
  • Henry Schein Inc.
  • ICU Medical Inc.
  • JW Life Science
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Salius Pharma Private Limited
  • Sichuan Kelun Pharmaceutical Co. Ltd
  • Soxa Formulations & Research（Pvt.）Ltd.
  • Vifor Pharma Management Ltd.
  • 其他
Product Code: 136853-05-23

Intravenous Solutions Market is Expected to Grow at 8.0% by 2031. Intravenous solutions present a combination of nutrients that support patients to get essential nutrition. The demand for intravenous solutions on the global front is undergoing steady growth and its market presents a higher growth in the Asia-Pacific region. Intravenous products are highly regulated for quality and availability assurance. Though matured, this market has been undergoing continuous evolution, thus experiencing steady growth.

The intravenous solutions manufacturers and vendors worldwide are perpetually improving the nature of products, and sales and distribution methods respectively. Several large players have employed direct sales force and independent distributors, retail and wholesalers. Alternate modes of supply are also employed by the manufacturers to retain profitability. Third parties that store and deliver products for the manufacturer have a significant foothold in developed markets. These type of vendors are found to better cater swift customer service as they always stock adequate inventories. Other sales practices in this market include sales through customer and sales service representatives, catalogue circulation and merchandising, electronic purchase facility and allied benefits, e-mail campaign, publicity through trade publications and trade fairs and others.

Market Players

Amanta Healthcare Ltd., Axa Parenterals Ltd., B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, Eurolife Healthcare Pvt Ltd.,Fresenius Kabi AG, Grifols S.A, Henry Schein Inc., ICU Medical, Inc., JW Life Science, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Salius Pharma Private Limited, Sichuan Kelun Pharmaceutical Co. Ltd, Soxa Formulations & Research (Pvt.) Ltd., Vifor Pharma Management Ltd. And Other Notable Players.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Intravenous Solutions market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Intravenous Solutions market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

  • Partial Parenteral Nutrition
    • Age Group
    • Pediatric
    • Adult
  • Total Parenteral Nutrition
    • Age Group
    • Pediatric
    • Adult

Composition

  • Carbohydrates
  • Vitamins and Minerals
  • Single Dose Amino Acids
  • Parenteral Lipid Emulsion
  • Others

End Users

  • Hospitals and Clinics
  • Ambulatory Surgery Centers
  • Home care settings

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Intravenous Solutions market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Intravenous Solutions market?
  • Which is the largest regional market for Intravenous Solutions market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Intravenous Solutions market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Intravenous Solutions market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Intravenous Solutions Market
  • 2.2. Global Intravenous Solutions Market, By Type, 2022 (US$ Million)
  • 2.3. Global Intravenous Solutions Market, By Composition, 2022 (US$ Million)
  • 2.4. Global Intravenous Solutions Market, By End Users, 2022 (US$ Million)
  • 2.5. Global Intravenous Solutions Market, By Geography, 2022 (US$ Million)
  • 2.6. Attractive Investment Proposition by Geography, 2022

3. Intravenous Solutions Market: Competitive Analysis

  • 3.1. Market Positioning of Key Intravenous Solutions Market Vendors
  • 3.2. Strategies Adopted by Intravenous Solutions Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Intravenous Solutions Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Intravenous Solutions Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Partial Parenteral Nutrition
      • 5.3.1.1. Age Group
        • 5.3.1.1.1. Pediatric
        • 5.3.1.1.2. Adult
    • 5.3.2. Total Parenteral Nutrition
      • 5.3.2.1. Age Group
        • 5.3.2.1.1. Pediatric
        • 5.3.2.1.2. Adult

6. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Carbohydrates
    • 6.3.2. Vitamins and Minerals
    • 6.3.3. Single Dose Amino Acids
    • 6.3.4. Parenteral Lipid Emulsion
    • 6.3.5. Others

7. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 7.3. Market Segmentation
    • 7.3.1. Hospitals and Clinics
    • 7.3.2. Ambulatory Surgery Centers
    • 7.3.3. Home care settings

8. North America Intravenous Solutions Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
  • 8.3. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
  • 8.4. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
  • 8.5.Intravenous Solutions Market: By Region, 2021-2031, USD (Million)
    • 8.5.1.North America
      • 8.5.1.1. U.S.
        • 8.5.1.1.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 8.5.1.1.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 8.5.1.1.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 8.5.1.2. Canada
        • 8.5.1.2.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 8.5.1.2.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 8.5.1.2.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 8.5.1.3. Rest of North America
        • 8.5.1.3.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 8.5.1.3.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 8.5.1.3.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

9. UK and European Union Intravenous Solutions Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
  • 9.3. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
  • 9.4. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
  • 9.5.Intravenous Solutions Market: By Region, 2021-2031, USD (Million)
    • 9.5.1.UK and European Union
      • 9.5.1.1. UK
        • 9.5.1.1.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.1.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.1.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 9.5.1.2. Germany
        • 9.5.1.2.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.2.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.2.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 9.5.1.3. Spain
        • 9.5.1.3.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.3.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.3.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 9.5.1.4. Italy
        • 9.5.1.4.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.4.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.4.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 9.5.1.5. France
        • 9.5.1.5.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.5.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.5.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 9.5.1.6. Rest of Europe
        • 9.5.1.6.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.6.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.6.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

10. Asia Pacific Intravenous Solutions Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
  • 10.3. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
  • 10.4. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
  • 10.5.Intravenous Solutions Market: By Region, 2021-2031, USD (Million)
    • 10.5.1.Asia Pacific
      • 10.5.1.1. China
        • 10.5.1.1.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.1.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.1.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 10.5.1.2. Japan
        • 10.5.1.2.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.2.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.2.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 10.5.1.3. India
        • 10.5.1.3.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.3.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.3.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 10.5.1.4. Australia
        • 10.5.1.4.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.4.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.4.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 10.5.1.5. South Korea
        • 10.5.1.5.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.5.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.5.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 10.5.1.6. Rest of Asia Pacific
        • 10.5.1.6.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.6.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.6.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

11. Latin America Intravenous Solutions Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
  • 11.3. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
  • 11.4. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
  • 11.5.Intravenous Solutions Market: By Region, 2021-2031, USD (Million)
    • 11.5.1.Latin America
      • 11.5.1.1. Brazil
        • 11.5.1.1.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 11.5.1.1.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 11.5.1.1.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 11.5.1.2. Mexico
        • 11.5.1.2.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 11.5.1.2.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 11.5.1.2.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 11.5.1.3. Rest of Latin America
        • 11.5.1.3.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 11.5.1.3.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 11.5.1.3.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

12. Middle East and Africa Intravenous Solutions Market, 2021-2031, USD (Million)

  • 12.1. Market Overview
  • 12.2. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
  • 12.3. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
  • 12.4. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
  • 12.5.Intravenous Solutions Market: By Region, 2021-2031, USD (Million)
    • 12.5.1.Middle East and Africa
      • 12.5.1.1. GCC
        • 12.5.1.1.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 12.5.1.1.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 12.5.1.1.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 12.5.1.2. Africa
        • 12.5.1.2.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 12.5.1.2.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 12.5.1.2.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 12.5.1.3. Rest of Middle East and Africa
        • 12.5.1.3.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 12.5.1.3.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 12.5.1.3.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

13. Company Profile

  • 13.1. Amanta Healthcare Ltd.
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Portfolio
    • 13.1.4. Strategic Initiatives
  • 13.2. Axa Parenterals Ltd.,
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Portfolio
    • 13.2.4. Strategic Initiatives
  • 13.3. B. Braun Melsungen AG
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Portfolio
    • 13.3.4. Strategic Initiatives
  • 13.4. Baxter International Inc.
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Portfolio
    • 13.4.4. Strategic Initiatives
  • 13.5. Becton, Dickinson and Company
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Portfolio
    • 13.5.4. Strategic Initiatives
  • 13.6. Eurolife Healthcare Pvt Ltd.
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Portfolio
    • 13.6.4. Strategic Initiatives
  • 13.7. Fresenius Kabi AG
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Portfolio
    • 13.7.4. Strategic Initiatives
  • 13.8. Grifols S.A
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Portfolio
    • 13.8.4. Strategic Initiatives
  • 13.9. Henry Schein Inc.
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Portfolio
    • 13.9.4. Strategic Initiatives
  • 13.10. ICU Medical, Inc.
    • 13.10.1. Company Overview
    • 13.10.2. Financial Performance
    • 13.10.3. Product Portfolio
    • 13.10.4. Strategic Initiatives
  • 13.11. JW Life Science
    • 13.11.1. Company Overview
    • 13.11.2. Financial Performance
    • 13.11.3. Product Portfolio
    • 13.11.4. Strategic Initiatives
  • 13.12. Otsuka Pharmaceutical Co., Ltd.
    • 13.12.1. Company Overview
    • 13.12.2. Financial Performance
    • 13.12.3. Product Portfolio
    • 13.12.4. Strategic Initiatives
  • 13.13. Pfizer, Inc.
    • 13.13.1. Company Overview
    • 13.13.2. Financial Performance
    • 13.13.3. Product Portfolio
    • 13.13.4. Strategic Initiatives
  • 13.14. Salius Pharma Private Limited
    • 13.14.1. Company Overview
    • 13.14.2. Financial Performance
    • 13.14.3. Product Portfolio
    • 13.14.4. Strategic Initiatives
  • 13.15. Sichuan Kelun Pharmaceutical Co. Ltd
    • 13.15.1. Company Overview
    • 13.15.2. Financial Performance
    • 13.15.3. Product Portfolio
    • 13.15.4. Strategic Initiatives
  • 13.16. Soxa Formulations & Research (Pvt.) Ltd.
    • 13.16.1. Company Overview
    • 13.16.2. Financial Performance
    • 13.16.3. Product Portfolio
    • 13.16.4. Strategic Initiatives
  • 13.17. Vifor Pharma Management Ltd.
    • 13.17.1. Company Overview
    • 13.17.2. Financial Performance
    • 13.17.3. Product Portfolio
    • 13.17.4. Strategic Initiatives
  • 13.18. Other Notable Players
    • 13.18.1. Company Overview
    • 13.18.2. Financial Performance
    • 13.18.3. Product Portfolio
    • 13.18.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 2 Global Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 3 Global Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 4 Global Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 5 Global Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 6 Global Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 7 Global Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 8 North America Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 9 North America Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 10 North America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 11 North America Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 12 North America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 13 North America Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 14 North America Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 15 U.S. Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 16 U.S. Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 17 U.S. Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 18 U.S. Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 19 U.S. Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 20 U.S. Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 21 U.S. Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 22 Canada Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 23 Canada Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 24 Canada Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 25 Canada Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 26 Canada Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 27 Canada Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 28 Canada Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 29 Rest of North America Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 30 Rest of North America Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 31 Rest of North America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 32 Rest of North America Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 33 Rest of North America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 34 Rest of North America Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 35 Rest of North America Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 36 UK and European Union Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 37 UK and European Union Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 38 UK and European Union Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 39 UK and European Union Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 40 UK and European Union Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 41 UK and European Union Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 42 UK and European Union Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 43 UK Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 44 UK Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 45 UK Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 46 UK Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 47 UK Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 48 UK Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 49 UK Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 50 Germany Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 51 Germany Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 52 Germany Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 53 Germany Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 54 Germany Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 55 Germany Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 56 Germany Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 57 Spain Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 58 Spain Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 59 Spain Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 60 Spain Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 61 Spain Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 62 Spain Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 63 Spain Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 64 Italy Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 65 Italy Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 66 Italy Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 67 Italy Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 68 Italy Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 69 Italy Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 70 Italy Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 71 France Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 72 France Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 73 France Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 74 France Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 75 France Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 76 France Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 77 France Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 78 Rest of Europe Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 79 Rest of Europe Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 80 Rest of Europe Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 81 Rest of Europe Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 82 Rest of Europe Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 83 Rest of Europe Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 84 Rest of Europe Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 85 Asia Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 86 Asia Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 87 Asia Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 88 Asia Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 89 Asia Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 90 Asia Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 91 Asia Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 92 China Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 93 China Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 94 China Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 95 China Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 96 China Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 97 China Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 98 China Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 99 Japan Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 100 Japan Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 101 Japan Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 102 Japan Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 103 Japan Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 104 Japan Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 105 Japan Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 106 India Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 107 India Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 108 India Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 109 India Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 110 India Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 111 India Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 112 India Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 113 Australia Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 114 Australia Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 115 Australia Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 116 Australia Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 117 Australia Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 118 Australia Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 119 Australia Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 120 South Korea Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 121 South Korea Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 122 South Korea Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 123 South Korea Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 124 South Korea Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 125 South Korea Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 126 South Korea Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 127 Latin America Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 128 Latin America Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 129 Latin America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 130 Latin America Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 131 Latin America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 132 Latin America Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 133 Latin America Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 134 Brazil Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 135 Brazil Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 136 Brazil Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 137 Brazil Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 138 Brazil Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 139 Brazil Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 140 Brazil Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 141 Mexico Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 142 Mexico Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 143 Mexico Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 144 Mexico Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 145 Mexico Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 146 Mexico Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 147 Mexico Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 148 Rest of Latin America Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 149 Rest of Latin America Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 150 Rest of Latin America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 151 Rest of Latin America Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 152 Rest of Latin America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 153 Rest of Latin America Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 154 Rest of Latin America Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 155 Middle East and Africa Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 156 Middle East and Africa Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 157 Middle East and Africa Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 158 Middle East and Africa Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 159 Middle East and Africa Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 160 Middle East and Africa Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 161 Middle East and Africa Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 162 GCC Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 163 GCC Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 164 GCC Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 165 GCC Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 166 GCC Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 167 GCC Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 168 GCC Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 169 Africa Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 170 Africa Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 171 Africa Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 172 Africa Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 173 Africa Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 174 Africa Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 175 Africa Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 176 Rest of Middle East and Africa Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 177 Rest of Middle East and Africa Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 178 Rest of Middle East and Africa Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 179 Rest of Middle East and Africa Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 180 Rest of Middle East and Africa Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 181 Rest of Middle East and Africa Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 182 Rest of Middle East and Africa Intravenous Solutions Market By End Users, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Intravenous Solutions Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Intravenous Solutions Market: Quality Assurance
  • FIG. 5 Global Intravenous Solutions Market, By Type, 2022
  • FIG. 6 Global Intravenous Solutions Market, By Composition, 2022
  • FIG. 7 Global Intravenous Solutions Market, By End Users, 2022
  • FIG. 8 Global Intravenous Solutions Market, By Geography, 2022
  • FIG. 9 Market Geographical Opportunity Matrix - Global Intravenous Solutions Market, 2022
  • FIG. 10 Market Positioning of Key Intravenous Solutions Market Players, 2022
  • FIG. 11 Global Intravenous Solutions Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
  • FIG. 12 Global Intravenous Solutions Market, By Type, 2022 Vs 2031, %
  • FIG. 13 Global Intravenous Solutions Market, By Composition, 2022 Vs 2031, %
  • FIG. 14 Global Intravenous Solutions Market, By End Users, 2022 Vs 2031, %
  • FIG. 15 U.S. Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 16 Canada Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 17 Rest of North America Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 18 UK Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 19 Germany Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 20 Spain Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 21 Italy Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 22 France Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 23 Rest of Europe Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 24 China Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 25 Japan Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 26 India Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 27 Australia Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 28 South Korea Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 29 Rest of Asia Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 30 Brazil Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 31 Mexico Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 32 Rest of Latin America Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 33 GCC Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 34 Africa Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 35 Rest of Middle East and Africa Intravenous Solutions Market (US$ Million), 2021 - 2031